- Home
- FOF vs PROK Comparison
FOF vs PROK Comparison
Compare FOF & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOF | PROK |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.8M | 417.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FOF | PROK |
|---|---|---|
| Price | $12.97 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 58.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $744,000.00 |
| Revenue This Year | N/A | $918.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $0.46 |
| 52 Week High | $11.75 | $7.13 |
Technical Indicators
Market Signals| Indicator | FOF | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 42.40 |
| Support Level | $12.87 | $2.09 |
| Resistance Level | $13.10 | $2.29 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 33.33 | 28.69 |
Price Performance
Historical ComparisonAbout FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.